Alnylam Pharmaceuticals (NASDAQ: ALNY) revenue
Alnylam Pharmaceuticals reported revenue of $3,714m for fiscal 2025, 65.2% more than in fiscal 2024 ($2,248m). Since fiscal 2016 its revenue has grown by 7,775.4%, an average growth of 62.4% a year.
Alnylam Pharmaceuticals has grown its revenue for 7 years in a row, and fiscal 2025 is the highest of its 10 fiscal years on record. The biggest drop was in fiscal 2018, −16.7%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $3,714m | +65.2% | $501.6m | 13.5% |
| 2024 | $2,248m | +23.0% | −$176.9m | −7.9% |
| 2023 | $1,828m | +76.2% | −$282.2m | −15.4% |
| 2022 | $1,037m | +22.9% | −$785.1m | −75.7% |
| 2021 | $844.3m | +71.3% | −$708.7m | −83.9% |
| 2020 | $492.9m | +124.3% | −$828.4m | −168.1% |
| 2019 | $219.8m | +193.4% | −$939.4m | −427.5% |
| 2018 | $74.9m | −16.7% | −$814.7m | −1,087.6% |
| 2017 | $89.9m | +90.7% | −$500.1m | −556.2% |
| 2016 | $47.2m | — | −$424.6m | −900.3% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Alnylam Pharmaceuticals revenue compared with its sector
By revenue for its latest fiscal year, Alnylam Pharmaceuticals ranks 76th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Alnylam Pharmaceuticals, 65.2%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 74th | Alignment Healthcare | $3,949m | 46.1% |
| 75th | AptarGroup | $3,777m | 5.4% |
| 76th | Alnylam Pharmaceuticals | $3,714m | 65.2% |
| 77th | Dentsply Sirona | $3,680m | −3.0% |
| 78th | Bruker | $3,437m | 2.1% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Alnylam Pharmaceuticals
- How much revenue did Alnylam Pharmaceuticals make in fiscal 2025?
- Alnylam Pharmaceuticals reported revenue of $3,714m for fiscal 2025, compared with $2,248m in fiscal 2024.
- How much has the revenue of Alnylam Pharmaceuticals grown?
- Between fiscal 2016 and fiscal 2025 it went from $47.2m to $3,714m: 7,775.4% more, an average growth of 62.4% a year.
- What was the best year for revenue at Alnylam Pharmaceuticals?
- Of its last 10 fiscal years, fiscal 2025, with $3,714m.
- Where does Alnylam Pharmaceuticals rank in its sector by revenue?
- It ranks 76th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Alnylam Pharmaceuticals come from?
- From the annual report (Form 10-K) that Alnylam Pharmaceuticals files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Alnylam Pharmaceuticals files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Alnylam Pharmaceuticals: the Alnylam Pharmaceuticals page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.